Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28933854 | 1.00 | USP30 (0.47) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL22765049 | 1.00 | USP30 (0.47) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL23761156 | 1.00 | USP30 (0.47) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL23751452 | 0.97 | USP30 (0.47) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL23751450 | 0.97 | USP30 (0.47) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL31497659 | 0.95 | USP30 (0.51) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL31609815 | 0.93 | GPR119 (0.46) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL31588721 | 0.93 | GPR119 (0.46) | USP30GPR119JAK2JAK1TACR1 | |
| SCHEMBL31588539 | 0.91 | USP30 (0.49) | USP30GPR119JAK2JAK1MMP9 | |
| SCHEMBL23761152 | 0.91 | USP30 (0.50) | USP30GPR119JAK2JAK1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441714-B2 | Pyrrolidine compounds | ELI LILLY AND COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2022-06-02 | — | — | US | disclosed |
| EP-3980409-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11286249-B2 | Pyrrolidine compounds | ELI LILLY AND COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| CN-114008021-A | Pyrrolidine compounds | 伊莱利利公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | USP30 3650/4885GPR119 3539/4885JAK2 112/4885 |
| US-12441714-B2 | Pyrrolidine compounds | ADCYAP1R1, AVPR2, NPPA | USP30 4139/4885GPR119 3273/4885JAK2 102/4885 |
| US-11286249-B2 | Pyrrolidine compounds | PAH, OTC, PPOX | USP30 3921/4885GPR119 3937/4885JAK2 284/4885 |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ADCYAP1R1, AVPR2, NPPA | USP30 4139/4885GPR119 3273/4885JAK2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.